Shopping Cart
- Remove All
- Your shopping cart is currently empty
Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance its degradation. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance its degradation. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2]. |
Cas No. | 2361290-85-7 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.